AMGA appoints Jerry Penso, M.D., president

value
Jerry Penso, M.D., will lead the AMGA as it continues to press for the transition to value-based care.

The AMGA didn’t have to look far for its new president and CEO.

Its board of directors has appointed Jerry Penso, M.D., who currently serves as president of the AMGA Foundation and chief medical and quality officer of AMGA, to the position. His appointment is effective Oct. 16, when Penso will take over leadership of the trade association that represents more than 450 multispecialty medical groups and integrated care systems and is advocating for the transformation of healthcare.

“New payment models, regulatory burdens, physician burnout, consolidation in the market and increased patient expectations for convenience and service are just a few of the challenges our members face,” Penso said in an announcement. His aim is for AMGA to help members navigate the transition to value-based and high-performance health models, he said.

Free Daily Newsletter

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

Prior to joining AMGA, Penso served as medical director, continuum of care for Sharp Rees-Stealy Medical Group, the largest integrated healthcare delivery system in San Diego.

Penso replaces Donald W. Fisher, Ph.D., who died in March 2017 and had served as AMGA president and CEO for more than 35 years.

Suggested Articles

Korunda Medical must pay $85,000 to the Department of Health and Human Services for taking too long to fulfill a patient's medical records request.

In order to make progress towards improving outcomes, the health care industry must be willing to open its doors to where our patients live.

CVS is launching a new program aimed at boosting access to genetic testing for people with advanced cancers.